Clearmind Medicine Inc. Common Shares (CMND) Dividend History

Company News

• Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight

  The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.

  GlobeNewswire Inc.

  Featured Companies: ADIL BTAI INDV
• SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

  SciSparc and Clearmind Medicine have filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disorders.

  GlobeNewswire Inc.
• Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

  Clearmind Medicine has filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) and Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disorders.

  GlobeNewswire Inc.
• Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

  Clearmind Medicine Inc. has been granted a patent by the Macau International Intellectual Property Office for its proprietary MEAI-based binge behavior regulator program. This patent further strengthens the company's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families.

  GlobeNewswire Inc.
• Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

  Clearmind Medicine Inc. has signed a non-binding term sheet with Dr Glitter Pty Ltd to collaborate on the development and commercialization of Clearmind's MEAI-based alcohol substitute using Dr Glitter's ActivCrystal™ technology. The partnership aims to provide a safe alternative to alcohol that can replicate the sensations of drinking without the associated health risks.

  GlobeNewswire Inc.